NICE is unable to make a recommendation about the use in the NHS of vernakalant for the rapid conversion of recent onset atrial fibrillation (7 days or less) to sinus rhythm in adults who have not had surgery. This is because Correvio Ltd did not provide an evidence submission for the appraisal. The company has confirmed that it does not intend to make a submission because it considers there is insufficient evidence.
If NHS organisations wish to consider vernakalant for the rapid conversion of recent onset atrial fibrillation (7 days or less) to sinus rhythm in adults who have not had surgery, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position if the company decides that it wants to make an evidence submission.